JR152JessicaAllegrettiJessica Ravikoff Allegretti, M.D.42.36241700000000-71.0689370000000078868Allegretti, JessicaRavikoff617/732-6389Associate Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 10495031129447696Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJCell host & microbeStrain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018 Feb 14; 23(2):229-240.e5.Cell Host Microbe2018-02-14T00:00:002018Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation.Authorship 10557501129594746Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Eliott R, Mitchell T, Kassam Z, Allegretti JR, Osman MCurrent gastroenterology reportsScaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018 03 28; 20(4):14.Curr Gastroenterol Rep2018-03-28T00:00:002018Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.Authorship 1066914429788102Merker AM, Riaz M, Friedman S, Allegretti JR, Korzenik JInflammatory bowel diseasesLegalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2309-2314.Inflamm Bowel Dis2018-10-12T00:00:002018Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease.Authorship 10736816Authorship 10724941029899513Kearney SM, Gibbons SM, Poyet M, Gurry T, Bullock K, Allegretti JR, Clish CB, Alm EJThe ISME journalEndospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota. ISME J. 2018 10; 12(10):2403-2416.ISME J2018-06-13T00:00:002018Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota.29884929Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Elliott R, Mitchell T, Kassam Z, Allegretti JR, Osman MCurrent gastroenterology reportsCorrection to: Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018 06 08; 20(7):28.Curr Gastroenterol Rep2018-06-08T00:00:002018Correction to: Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.Authorship 10873622330085388Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer MAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsFecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant. 2019 02; 19(2):501-511.Am J Transplant2018-08-31T00:00:002018Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.Authorship 1096893330268564Krajicek E, Fischer M, Allegretti JR, Kelly CRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationNuts and Bolts of Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2019 01; 17(2):345-352.Clin Gastroenterol Hepatol2018-09-27T00:00:002018Nuts and Bolts of Fecal Microbiota Transplantation.22241674Ravikoff JE, Cole EB, Korzenik JRInflammatory bowel diseasesBarriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis. 2012 Nov; 18(11):2092-8.Inflamm Bowel Dis2012-01-12T00:00:002012Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives.Authorship 1117019130519847Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam ZDigestive diseases and sciencesFecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose. Dig Dis Sci. 2019 06; 64(6):1672-1678.Dig Dis Sci2018-12-05T00:00:002018Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose.2021-07-31SNAPPER, SCOTT B2018-08-21Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitisR21DK118951Authorship 1124394130632052Allegretti JR, Kao D, Phelps E, Roach B, Smith J, Ganapini VC, Kassam Z, Xu H, Fischer MDigestive diseases and sciencesRisk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis? Dig Dis Sci. 2019 06; 64(6):1668-1671.Dig Dis Sci2019-01-10T00:00:002019Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?30882536Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WWJournal of clinical gastroenterologyRisk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 10; 53(9):e405-e408.J Clin Gastroenterol2019-10-01T00:00:002019Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).Authorship 11390051Authorship 11376851Authorship 1139463430778870Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam ZDigestive diseases and sciencesCorrection to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose. Dig Dis Sci. 2019 Jul; 64(7):2059.Dig Dis Sci2019-07-01T00:00:002019Correction to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose.30816855Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, Thursz MR, Marchesi JRGutMicrobial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. 2019 10; 68(10):1791-1800.Gut2019-02-11T00:00:002019Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection.D015212Disorders71623970.342892Inflammatory Bowel DiseasesD003015Disorders2225490.592006Clostridium InfectionsD003424Disorders67622990.388263Crohn DiseaseAuthorship 11430131Authorship 1144666230906424Levy AN, Allegretti JRTherapeutic advances in gastroenterologyInsights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. 2019; 12:1756284819836893.Therap Adv Gastroenterol2019-03-14T00:00:002019Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease.30730351Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, Korzenik JRThe American journal of gastroenterologyFecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019 07; 114(7):1071-1079.Am J Gastroenterol2019-07-01T00:00:002019Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial.D003093Disorders51318990.407657Colitis, UlcerativeD005243Anatomy57713890.625665FecesMedicinePediatricsGastroenterologyCardiologyVA Med CentersRenalBeth Israel Deaconess Medical CenterBrigham and Women's HospitalBoston Children's HospitalMassachusetts General HospitalRX1RamnikXavierRamnik Xavier, M.B.,B.Ch.42.36125700000000-71.0655270000000064506Xavier, RamnikKurt J. Isselbacher Professor of Medicine in the Field of Gastroenterology11136selected publications14.01580.0102961224research areas20.5210.035115240coauthor of541.68827.98860similar toCJO1ChristopherO'DonnellChristopher Joseph O'Donnell, M.D.42.36241700000000-71.068937000000007288O'Donnell, ChristopherSenior Lecturer on Medicine, Part-timeJK78JoshuaKorzenikJoshua Korzenik, M.D.42.36127360000000-71.0647979000000081506Korzenik, JoshuaAssociate Professor of MedicineAuthorship 1155712231122134McSweeney B, Allegretti JR, Fischer M, Xu H, Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL, Chis R, Edmison A, Juby A, Ennis-Davis R, Roach B, Wong K, Kao DGut microbesIn search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes. 2020; 11(1):51-62.Gut Microbes2019-05-23T00:00:002019In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation.CPK1CiaranKellyCiaran Patrick Kelly, M.B., M.D.42.34022770000000-71.105854000000005983Kelly, CiaranProfessor of MedicineHK133HamedKhaliliHamed Khalili, M.D.42.36241700000000-71.0689370000000036623Khalili, HamedAssociate Professor of MedicineANA8AshwinAnanthakrishnanAshwin N Ananthakrishnan, M.B.,B.S.42.36127360000000-71.0647979000000091281Ananthakrishnan, AshwinAssociate Professor of MedicineEAS37EsperanceSchaeferEsperance Anne Kreek Schaefer, M.D.42.36241700000000-71.0689370000000044096Schaefer, EsperanceInstructor in MedicineAG21AnnaGrekaAnna Greka, M.D., Ph.D.42.36241700000000-71.0689370000000027315Greka, AnnaProfessor of MedicineCGT4CarloTraversoCarlo Giovanni Traverso, M.B.,B.S., Ph.D.42.36241700000000-71.068937000000003838Traverso, CarloAssistant Professor of Medicine, Part-timeWWC2WalterChanWalter Wai-Yip Chan, M.D.42.33510370000000-71.106164900000007519Chan, WalterAssociate Professor of MedicineMJH28MatthewHamiltonMatthew J. Hamilton, M.D.42.33510370000000-71.1061649000000033393Hamilton, MatthewAssistant Professor of MedicineRCD6RahulDeoRahul Chandrakant Deo, M.D., Ph.D.42.36241700000000-71.0689370000000046119Deo, RahulLecturer on Medicine, Part-timeAuthorship 1167303431254675Kelly CR, Fischer M, Grinspan A, Allegretti JRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationPatients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 05; 18(5):1099-1101.Clin Gastroenterol Hepatol2019-06-27T00:00:002019Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection.RSD14RahulDalalRahul Sanjay Dalal, M.D.181937Dalal, RahulInstructor in MedicineAuthorship 11733681Authorship 1173621131301451Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguéns Blanco J, Garcia-Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson CClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationEffects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020 04; 18(4):855-863.e2.Clin Gastroenterol Hepatol2019-07-10T00:00:002019Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients.31306151Allegretti JR, Kassam ZThe American journal of gastroenterologyFecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story. Am J Gastroenterol. 2019 08; 114(8):1354-1355.Am J Gastroenterol2019-08-01T00:00:002019Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story.Authorship 11795241Authorship 1179487331384699Santiago M, Eysenbach L, Allegretti J, Aroniadis O, Brandt LJ, Fischer M, Grinspan A, Kelly C, Morrow C, Rodriguez M, Osman M, Kassam Z, Smith MB, Timberlake SAIMS microbiologyMicrobiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiol. 2019; 5(1):1-18.AIMS Microbiol2019-01-17T00:00:002019Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study.31379333Allegretti JR, Mullish BH, Kelly C, Fischer MLancet (London, England)The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019 08 03; 394(10196):420-431.Lancet2019-08-03T00:00:002019The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.Authorship 11948142Authorship 1195833531563878Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini AGutInternational consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019 12; 68(12):2111-2121.Gut2019-09-28T00:00:002019International consensus conference on stool banking for faecal microbiota transplantation in clinical practice.31570017Elangovan A, Allegretti JR, Fischer MExpert opinion on biological therapyMicrobiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opin Biol Ther. 2019 12; 19(12):1343-1355.Expert Opin Biol Ther2019-10-13T00:00:002019Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation.Authorship 1196715431616747Hathorn K, Qazi T, Caton MT, Allegretti JRACG case reports journalCryptogenic Multifocal Ulcerative Sclerosing Enteritis: A Curious Case of Intestinal Obstruction in the Setting of Human Immunodeficiency Virus. ACG Case Rep J. 2019 May; 6(5):e00070.ACG Case Rep J2019-05-14T00:00:002019Cryptogenic Multifocal Ulcerative Sclerosing Enteritis: A Curious Case of Intestinal Obstruction in the Setting of Human Immunodeficiency Virus.Authorship 12012581Authorship 1200810931665572Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman MThe New England journal of medicineDonor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 11 21; 381(21):2070-2072.N Engl J Med2019-10-30T00:00:002019Donor Screening for Fecal Microbiota Transplantation.31667694Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, Bry LDigestive diseases and sciencesClinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study. Dig Dis Sci. 2020 06; 65(6):1761-1766.Dig Dis Sci2019-10-30T00:00:002019Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study.true1Kurt J. Isselbacher Professor of Medicine in the Field of GastroenterologyKurt J. Isselbacher Professor of Medicine in the Field of Gastroenterologytrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Assistant Professor of Medicine, Part-timeAssistant Professor of Medicine, Part-timetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 1216906831923639Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, El-Halabi M, Allegretti JR, Kassam Z, Xu H, Fischer MClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationFecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 09; 18(10):2234-2243.e1.Clin Gastroenterol Hepatol2020-01-08T00:00:002020Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection.Authorship 1218391231945351Singh S, Allegretti JR, Siddique SM, Terdiman JPGastroenterologyAGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 04; 158(5):1465-1496.e17.Gastroenterology2020-01-13T00:00:002020AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Authorship 1221452131982069Allegretti JR, Mullish BHLancet (London, England)Faecal microbiota transplantations and urinary tract infections - Authors' reply. Lancet. 2020 01 25; 395(10220):271.Lancet2020-01-25T00:00:002020Faecal microbiota transplantations and urinary tract infections - Authors' reply.Authorship 1223984432011405Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, Krajiceck E, Kumar V, Marcus J, Nativ L, Kelly CRJournal of clinical gastroenterologyLong-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2020 09; 54(8):701-706.J Clin Gastroenterol2020-09-01T00:00:002020Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection.Authorship 1225454332083498Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota GExpert opinion on biological therapyFecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther. 2020 04; 20(4):343-351.Expert Opin Biol Ther2020-02-26T00:00:002020Fecal transplantation for ulcerative colitis: current evidence and future applications.Authorship 12316451Authorship 1232979832170474Allegretti JR, Mehta SR, Kassam Z, Kelly CR, Kao D, Xu H, Fischer MDigestive diseases and sciencesRisk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. Dig Dis Sci. 2021 01; 66(1):213-217.Dig Dis Sci2020-03-13T00:00:002020Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection.32192627Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota GThe lancet. Gastroenterology & hepatologyScreening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020 05; 5(5):430-432.Lancet Gastroenterol Hepatol2020-03-17T00:00:002020Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.2025-01-31ALLEGRETTI, JESSICA R.2020-05-01Understanding Clostridium difficile Infection in Patients with inflammatory Bowel DiseaseK23DK120898Co-Principal InvestigatorPrincipal InvestigatorAuthorship 1256865132552337Allegretti JR, Elliott RJ, Ladha A, Njenga M, Warren K, O'Brien K, Budree S, Osman M, Fischer M, Kelly CR, Kassam ZGut microbesStool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. Gut Microbes. 2020 11 01; 11(6):1806-1808.Gut Microbes2020-06-18T00:00:002020Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation.Authorship 1260566832620549Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota GGutReorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020 09; 69(9):1555-1563.Gut2020-07-03T00:00:002020Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.Authorship 12655122232645451Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer MClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationFecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1627-1634.Clin Gastroenterol Hepatol2020-07-06T00:00:002020Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.Authorship 1267718532661762Gupta S, Aihara H, Trivedi HD, Srivastava A, Allegretti JR, Hamilton MJDigestive diseases and sciencesHeading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. Dig Dis Sci. 2020 10; 65(10):2818-2822.Dig Dis Sci2020-10-01T00:00:002020Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis.Authorship 1273515132738249Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Kassam Z, Fischer MGastroenterologyOutcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection. Gastroenterology. 2020 11; 159(5):1982-1984.Gastroenterology2020-07-30T00:00:002020Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection.Authorship 1287308532893721Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, Thursz MR, Marchesi JR, Mullish BHGut microbesUnderstanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes. 2020 11 09; 12(1):1810531.Gut Microbes2020-11-09T00:00:002020Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites.Authorship 1291249232987284Proença IM, Allegretti JR, Bernardo WM, de Moura DTH, Ponte Neto AM, Matsubayashi CO, Flor MM, Kotinda APST, de Moura EGHNutrition research (New York, N.Y.)Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020 11; 83:1-14.Nutr Res2020-07-03T00:00:002020Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials.Authorship 12931181633011173Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine LGastroenterologyFecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.Gastroenterology2020-10-01T00:00:002020Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry.33089863Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan ANInflammatory bowel diseasesImmunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 01 19; 27(2):155-161.Inflamm Bowel Dis2021-01-19T00:00:002021Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.Authorship 1296982333146703Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JRInflammatory bowel diseasesPredictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. Inflamm Bowel Dis. 2021 07 27; 27(8):1294-1301.Inflamm Bowel Dis2021-07-27T00:00:002021Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.Authorship 13076055Authorship 1303310133155639Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, Marcus J, Marchesi JR, McDonald JAK, Gerardin Y, Silverstein M, Pechlivanis A, Barker GF, Miguens Blanco J, Alexander JL, Gallagher KI, Pettee W, Phelps E, Nemes S, Sagi SV, Bohm M, Kassam Z, Fischer MInflammatory bowel diseasesInflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis. 2021 08 19; 27(9):1371-1378.Inflamm Bowel Dis2021-08-19T00:00:002021Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.33330910Gerardin Y, Timberlake S, Allegretti JR, Smith MB, Kassam ZThe Journal of infectious diseasesBeyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome. J Infect Dis. 2021 06 16; 223(12 Suppl 2):S276-S282.J Infect Dis2021-06-16T00:00:002021Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome.Authorship 13101343Authorship 1317704133420959Allegretti JR, Kassam Z, Hurtado J, Marchesi JR, Mullish BH, Chiang A, Thompson CC, Cummings BPHormones (Athens, Greece)Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021 Mar; 20(1):209-211.Hormones (Athens)2021-01-09T00:00:002021Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity.33501941Dalal RS, Allegretti JRInflammatory bowel diseasesFecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause? Inflamm Bowel Dis. 2021 10 20; 27(11):1873-1875.Inflamm Bowel Dis2021-10-20T00:00:002021Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?Authorship 132387922025-06-30ALLEGRETTI, JESSICA R.;SNAPPER, SCOTT B2020-09-01Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn's DiseaseR01DK126448Co-Principal Investigator33549869Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationCOVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 08; 19(8):1730-1732.e2.Clin Gastroenterol Hepatol2021-02-04T00:00:002021COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.33570151Dalal RS, Allegretti JRInflammatory bowel diseasesUstekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflamm Bowel Dis. 2021 05 17; 27(6):e70.Inflamm Bowel Dis2021-05-17T00:00:002021Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All.33570095Winter RW, Ananthakrishnan A, Burke KE, Kochar B, Chan WW, Allegretti JRInflammatory bowel diseasesTime to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 03 15; 27(4):590-592.Inflamm Bowel Dis2021-03-15T00:00:002021Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases.Authorship 13274982Authorship 13283928Authorship 13289813Authorship 13287796Authorship 1329163633577875Fujimoto K, Kimura Y, Allegretti JR, Yamamoto M, Zhang YZ, Katayama K, Tremmel G, Kawaguchi Y, Shimohigoshi M, Hayashi T, Uematsu M, Yamaguchi K, Furukawa Y, Akiyama Y, Yamaguchi R, Crowe SE, Ernst PB, Miyano S, Kiyono H, Imoto S, Uematsu SGastroenterologyFunctional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology. 2021 05; 160(6):2089-2102.e12.Gastroenterology2021-02-09T00:00:002021Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation.33571456Ianiro G, Mullish BH, Hvas CL, Segal JP, Kuijper EJ, Costello SP, Kelly CR, Allegretti JR, Fischer M, Iqbal TH, Satokari R, Kao D, van Prehn J, Ng SC, Bibbò S, Baunwall SMD, Quraishi MN, Sokol H, Zhang F, Keller J, Masucci L, Quaranta G, Kassam Z, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota GThe lancet. Gastroenterology & hepatologySARS-CoV-2 vaccines and donor recruitment for FMT. Lancet Gastroenterol Hepatol. 2021 04; 6(4):264-266.Lancet Gastroenterol Hepatol2021-02-08T00:00:002021SARS-CoV-2 vaccines and donor recruitment for FMT.Authorship 1331093333606488Gupta S, Mullish BH, Allegretti JRThe American journal of gastroenterologyFecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 Feb 05.Am J Gastroenterol2021-02-05T00:00:002021Fecal Microbiota Transplantation: The Evolving Risk Landscape.Authorship 1335309233654015Dalal RS, Allegretti JRCurrent opinion in gastroenterologyDiagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol. 2021 07 01; 37(4):336-343.Curr Opin Gastroenterol2021-07-01T00:00:002021Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.Authorship 1337091833682170Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JRJournal of gastroenterology and hepatologyCost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol. 2021 Sep; 36(9):2432-2440.J Gastroenterol Hepatol2021-03-17T00:00:002021Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection.Authorship 1345376633775893Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationPredictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2022 Oct; 20(10):2399-2401.e4.Clin Gastroenterol Hepatol2021-03-26T00:00:002021Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.34013064Allegretti JR, Nije C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WWJGH open : an open access journal of gastroenterology and hepatologyPrevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH Open. 2021 May; 5(5):622-625.JGH Open2021-03-30T00:00:002021Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019.Authorship 13567624Authorship 13565703Authorship 13556323Authorship 1355826133988235Dalal RS, Mitri J, Goodrick H, Allegretti JRInflammatory bowel diseasesReal-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflamm Bowel Dis. 2021 10 18; 27(10):1694-1697.Inflamm Bowel Dis2021-10-18T00:00:002021Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis.33982930Gupta S, Mullish BH, Allegretti JRThe American journal of gastroenterologyFecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 04; 116(4):647-656.Am J Gastroenterol2021-04-01T00:00:002021Fecal Microbiota Transplantation: The Evolving Risk Landscape.34003176Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NHThe American journal of gastroenterologyACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021 06 01; 116(6):1124-1147.Am J Gastroenterol2021-06-01T00:00:002021ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.Authorship 1359530134035760Allegretti JRGastroenterology & hepatologyUpdate on Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2021 Jan; 17(1):31-34.Gastroenterol Hepatol (N Y)2021-01-01T00:00:002021Update on Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease.Authorship 1363053234104212Mullish BH, Allegretti JRTherapeutic advances in gastroenterologyThe contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14:17562848211017725.Therap Adv Gastroenterol2021-05-28T00:00:002021The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection.Authorship 13648265Authorship 1364762134126262Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KEClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationAnti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021 11; 19(11):2324-2332.e6.Clin Gastroenterol Hepatol2021-06-12T00:00:002021Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.34142700Allegretti JR, Canakis A, McClure E, Marcus J, Norton BA, Hamilton MJ, Winter RW, De Silva PS, Friedman S, Korzenik JRInflammatory bowel diseasesInfliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Inflamm Bowel Dis. 2021 11 15; 27(12):2031-2033.Inflamm Bowel Dis2021-11-15T00:00:002021Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated.Authorship 1372625534245267Dalal RS, Gupta S, Goodrick H, Mitri J, Allegretti JRInflammatory bowel diseasesOutcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflamm Bowel Dis. 2022 01 05; 28(1):146-149.Inflamm Bowel Dis2022-01-05T00:00:002022Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders.Authorship 13890231434427649Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KEInflammatory bowel diseasesAntitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis. 2022 03 02; 28(3):434-446.Inflamm Bowel Dis2022-03-02T00:00:002022Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.Authorship 1405315334658366Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NHThe American journal of gastroenterologyCorrection to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2022 02 01; 117(2):358.Am J Gastroenterol2022-02-01T00:00:002022Correction to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.true1Associate Professor of MedicineAssociate Professor of Medicine35006199Dalal R, Mitri J, Goodrick H, Allegretti JThe American journal of gastroenterologyP074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S19.Am J Gastroenterol2021-12-01T00:00:002021P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.Authorship 14255344RW98RachelWinterRachel Winter, M.D.119067Winter, RachelAssistant Professor of MedicineAuthorship 1430299335137698Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NThe American journal of gastroenterologyResponse to McFarland et al. Am J Gastroenterol. 2022 03 01; 117(3):501-502.Am J Gastroenterol2022-03-01T00:00:002022Response to McFarland et al.Authorship 259998Authorship 14497265Authorship 14466662Authorship 1447703435398345Osman M, Budree S, Kelly CR, Panchal P, Allegretti JR, Kassam ZGastroenterologyEffectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study. Gastroenterology. 2022 07; 163(1):319-322.Gastroenterology2022-04-07T00:00:002022Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study.35415826Dalal RS, McClure EL, Marcus J, Allegretti JRDigestive diseases and sciencesComparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. Dig Dis Sci. 2023 01; 68(1):223-232.Dig Dis Sci2022-04-12T00:00:002022Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.35397501Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan NBMC gastroenterologyReal-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022 Apr 09; 22(1):177.BMC Gastroenterol2022-04-09T00:00:002022Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.Authorship 1451054235595413Gupta S, Allegretti JRGastroenterology clinics of North AmericaMimics of Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):241-269.Gastroenterol Clin North Am2022-04-27T00:00:002022Mimics of Crohn's Disease.true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 14599092Authorship 14681065Authorship 14616212Authorship 14671103Authorship 1467845335681218Dawkins JJ, Allegretti JR, Gibson TE, McClure E, Delaney M, Bry L, Gerber GKMicrobiomeGut metabolites predict Clostridioides difficile recurrence. Microbiome. 2022 06 09; 10(1):87.Microbiome2022-06-09T00:00:002022Gut metabolites predict Clostridioides difficile recurrence.35905034Shore BM, Weaver KN, Allegretti JR, Herfarth HH, Barnes ELInflammatory bowel diseasesPrevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch. Inflamm Bowel Dis. 2023 06 01; 29(6):932-937.Inflamm Bowel Dis2023-06-01T00:00:002023Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch.35792486Dalal RS, Bains K, Marcus J, McClure EL, Allegretti JRInflammatory bowel diseasesTofacitinib for the Treatment of Pouch-Related Disorders: A Case Series. Inflamm Bowel Dis. 2022 11 02; 28(11):1787-1789.Inflamm Bowel Dis2022-11-02T00:00:002022Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series.35883049Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan NBMC gastroenterologyCorrection to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022 Jul 26; 22(1):356.BMC Gastroenterol2022-07-26T00:00:002022Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.35907202Dalal RS, Pruce JC, Allegretti JRInflammatory bowel diseasesLong-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2023 05 02; 29(5):830-833.Inflamm Bowel Dis2023-05-02T00:00:002023Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases.true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 15003136Authorship 14845404Authorship 15032148Authorship 14784982Authorship 14905104Authorship 14822484Authorship 14839671Authorship 14997291336152634Allegretti JRThe lancet. Gastroenterology & hepatologyShould faecal microbiota transplantation be used earlier in the treatment framework? Lancet Gastroenterol Hepatol. 2022 Dec; 7(12):1062-1063.Lancet Gastroenterol Hepatol2022-09-22T00:00:002022Should faecal microbiota transplantation be used earlier in the treatment framework?36250604Mullish BH, Martinez-Gili L, Chekmeneva E, Correia GDS, Lewis MR, Horneffer-Van Der Sluis V, Roberts LA, McDonald JAK, Pechlivanis A, Walters JRF, McClure EL, Marchesi JR, Allegretti JRAlimentary pharmacology & therapeuticsAssessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection. Aliment Pharmacol Ther. 2022 12; 56(11-12):1556-1569.Aliment Pharmacol Ther2022-10-17T00:00:002022Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection.36140013Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MHAntibiotics (Basel, Switzerland)SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics (Basel). 2022 Sep 10; 11(9).Antibiotics (Basel)2022-09-10T00:00:002022SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).36336750Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JRThe patientLong-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 03; 16(2):95-103.Patient2022-11-07T00:00:002022Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.36156528Dalal RS, Mitri J, Goodrick H, Allegretti JRJournal of clinical gastroenterologyRisk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFa Agents for Ulcerative Colitis. J Clin Gastroenterol. 2023 08 01; 57(7):714-720.J Clin Gastroenterol2023-08-01T00:00:002023Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFa Agents for Ulcerative Colitis.36126907Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, McClure E, Kabage AJ, Khoruts AClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationEffectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2023 05; 21(5):1330-1337.e2.Clin Gastroenterol Hepatol2022-09-17T00:00:002022Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.35989897Montano-Loza AJ, Allegretti JR, Cheung A, Ebadi M, Jones D, Kerkar N, Levy C, Rizvi S, Vierling JM, Alvarez F, Bai W, Gilmour S, Gulamhusein A, Guttman O, Hansen BE, MacParland S, Mason A, Onofrio F, Santamaria P, Stueck A, Swain M, Vincent C, Ricciuto A, Hirschfield GCanadian liver journalSingle Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Can Liver J. 2021; 4(4):401-425.Can Liver J2021-11-11T00:00:002021Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.26952584Beltrami R, Chiesa M, Scribante A, Allegretti J, Poggio CJournal of applied biomaterials & functional materialsComparison of shear bond strength of universal adhesives on etched and nonetched enamel. J Appl Biomater Funct Mater. 2016 Apr 06; 14(1):e78-83.J Appl Biomater Funct Mater2016-04-06T00:00:002016Comparison of shear bond strength of universal adhesives on etched and nonetched enamel.Authorship 1509665336480711Mullish BH, Martinez-Gili L, Allegretti JRAlimentary pharmacology & therapeuticsEditorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply. Aliment Pharmacol Ther. 2023 01; 57(1):169-170.Aliment Pharmacol Ther2023-01-01T00:00:002023Editorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply.true1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 15121741036558359Bustamante JM, Dawson T, Loeffler C, Marfori Z, Marchesi JR, Mullish BH, Thompson CC, Crandall KA, Rahnavard A, Allegretti JR, Cummings BPNutrientsImpact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans. Nutrients. 2022 Dec 07; 14(24).Nutrients2022-12-07T00:00:002022Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans.Authorship 1519091236695753Feuerstadt P, Allegretti JR, Khanna SThe American journal of gastroenterologyPractical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 08 01; 118(8):1303-1306.Am J Gastroenterol2023-01-25T00:00:002023Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection.Authorship 15258292Authorship 1523941236755231Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KBBMC gastroenterologyTofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore. BMC Gastroenterol. 2023 Feb 08; 23(1):34.BMC Gastroenterol2023-02-08T00:00:002023Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.36791167Chang LL, Allegretti J, Skinner AM, Dubberke ERThe New England journal of medicineOral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection. N Engl J Med. 2023 02 16; 388(7):654-656.N Engl J Med2023-02-16T00:00:002023Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection.true1Senior Lecturer on Medicine, Part-timeSenior Lecturer on Medicine, Part-time37030335Allegretti JR, Mitsialis V, Canavan JB, Snapper SBGastroenterologyLow-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2023 08; 165(2):492-495.e2.Gastroenterology2023-04-07T00:00:002023Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis.true1Instructor in MedicineInstructor in MedicineAuthorship 15673233Authorship 15520763Authorship 15629161Authorship 15560954Authorship 15702815Authorship 15610876Authorship 15442015Authorship 1568791537498971Dalal RS, Kallumkal G, Cabral HJ, Bachour S, Barnes EL, Allegretti JRInflammatory bowel diseasesClinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Inflamm Bowel Dis. 2023 Jul 27.Inflamm Bowel Dis2023-07-27T00:00:002023Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.36990294Kralicek SE, Jenkins C, Allegretti JR, Lewis JD, Osman M, Hecht GAGastroenterologyTransmission of the Potential Pathogen Atypical Enteropathogenic Escherichia coli by Fecal Microbiota Transplant. Gastroenterology. 2023 Jul; 165(1):279-282.e1.Gastroenterology2023-03-28T00:00:002023Transmission of the Potential Pathogen Atypical Enteropathogenic Escherichia coli by Fecal Microbiota Transplant.37428414Dalal RS, Ermann J, Carlin A, Mitri J, Allegretti JRClinical rheumatologyActivity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases. Clin Rheumatol. 2023 Nov; 42(11):3001-3006.Clin Rheumatol2023-07-10T00:00:002023Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.37209416Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JRInflammatory bowel diseases1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. Inflamm Bowel Dis. 2024 Mar 01; 30(3):395-401.Inflamm Bowel Dis2024-03-01T00:00:0020241-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.37461990Dalal R, Mitri J, Goodrick H, Allegretti JThe American journal of gastroenterologyP074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S19.Am J Gastroenterol2021-12-01T00:00:002021P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.37091531Bachour SP, Dalal R, Allegretti JRTherapeutic advances in gastroenterologyThe impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therap Adv Gastroenterol. 2023; 16:17562848231165581.Therap Adv Gastroenterol2023-04-17T00:00:002023The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation.8502091Ness JA, Stankiewicz JA, Kaniff T, Pifarre R, Allegretti JThe LaryngoscopeSensorineural hearing loss associated with aortocoronary bypass surgery: a prospective analysis. Laryngoscope. 1993 Jun; 103(6):589-93.Laryngoscope1993-06-01T00:00:001993Sensorineural hearing loss associated with aortocoronary bypass surgery: a prospective analysis.Authorship 15910652Authorship 15882006Authorship 15854805Authorship 15844451Authorship 15917966Authorship 15834565Authorship 1593264237523667Dalal RS, Lund K, Zegers FD, Friedman S, Allegretti JR, Nørgård BMInflammatory bowel diseasesUse of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study. Inflamm Bowel Dis. 2023 Jul 31.Inflamm Bowel Dis2023-07-31T00:00:002023Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study.37619234Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JRInflammatory bowel diseases1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States. Inflamm Bowel Dis. 2023 Aug 24.Inflamm Bowel Dis2023-08-24T00:00:0020231-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States.37549387Kanjee Z, Allegretti JR, Alonso CD, Burns RBAnnals of internal medicineHow Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2023 08; 176(8):1101-1108.Ann Intern Med2023-08-08T00:00:002023How Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.37673349Dalal RS, Kallumkal G, Cabral HJ, Bachour S, Barnes EL, Allegretti JRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationComparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2024 Mar; 22(3):666-668.Clin Gastroenterol Hepatol2023-09-05T00:00:002023Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.37659673Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass AGastroenterologyGuselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 Dec; 165(6):1443-1457.Gastroenterology2023-09-01T00:00:002023Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.37713526Dalal RS, Nørgård BM, Zegers FD, Kjeldsen J, Friedman S, Allegretti JR, Lund KThe American journal of gastroenterologyOlder Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study. Am J Gastroenterol. 2024 Feb 01; 119(2):323-330.Am J Gastroenterol2023-10-02T00:00:002023Older Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study.37566894Allegretti JR, Khanna S, Feuerstadt PThe American journal of gastroenterologyPractical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 12 01; 118(12):2106-2108.Am J Gastroenterol2023-08-10T00:00:002023Practical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection.true1Instructor in MedicineInstructor in Medicinetrue1Professor of MedicineProfessor of MedicineAuthorship 1601555537843044Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JRInflammatory bowel diseasesClinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflamm Bowel Dis. 2023 Oct 16.Inflamm Bowel Dis2023-10-16T00:00:002023Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.Authorship 16098281Authorship 1609261237953548Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PMJournal of gastroenterology and hepatologyEarly recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. J Gastroenterol Hepatol. 2024 Feb; 39(2):264-271.J Gastroenterol Hepatol2023-11-12T00:00:002023Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.38051967Kelly CR, Allegretti JRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaReview Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future. Clin Infect Dis. 2023 Dec 05; 77(Supplement_6):S463-S470.Clin Infect Dis2023-12-05T00:00:002023Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.Authorship 1614263238110062Singh S, Allegretti J, Nersesova Y, Serra S, Kim AClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationMeeting Summary: AGA Roundtable on Clinical Trial Design in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 Dec 16.Clin Gastroenterol Hepatol2023-12-16T00:00:002023Meeting Summary: AGA Roundtable on Clinical Trial Design in Inflammatory Bowel Disease.Authorship 16170762Authorship 1616547238153224Newman KL, Allegretti JRThe American journal of gastroenterologyEmerging Noninfectious Indications for Live Biotherapeutic Products in Gastroenterology. Am J Gastroenterol. 2024 Jan 01; 119(1S):S30-S35.Am J Gastroenterol2024-01-01T00:00:002024Emerging Noninfectious Indications for Live Biotherapeutic Products in Gastroenterology.38142413Dalal RS, Allegretti JRInflammatory bowel diseasesReply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? Inflamm Bowel Dis. 2024 Mar 01; 30(3):516.Inflamm Bowel Dis2024-03-01T00:00:002024Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?Authorship 1621734238236515Feuerstadt P, Allegretti JR, Dubberke ER, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke LL, LaPlante K, Garey KW, Khanna SInfectious diseases and therapyEfficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infect Dis Ther. 2024 Jan; 13(1):221-236.Infect Dis Ther2024-01-18T00:00:002024Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.true1Lecturer on Medicine, Part-timeLecturer on Medicine, Part-timeAuthorship 1629523638408096Dalal RS, Winter RW, Gupta S, Sasson GF, Hamilton MJ, Allegretti JRInflammatory bowel diseasesClinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States. Inflamm Bowel Dis. 2024 Feb 26.Inflamm Bowel Dis2024-02-26T00:00:002024Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States.true1Assistant Professor of PediatricsAssistant Professor of PediatricsAuthorship 355386Authorship 729654124707129Allegretti JR, Hamilton MJWorld journal of gastroenterologyRestoring the gut microbiome for the treatment of inflammatory bowel diseases. World J Gastroenterol. 2014 Apr 07; 20(13):3468-74.World J Gastroenterol2014-04-07T00:00:002014Restoring the gut microbiome for the treatment of inflammatory bowel diseases.Gastroenterology & NutritionAuthorship 778553125549239Allegretti JR, Korzenik JR, Hamilton MJJournal of visualized experiments : JoVEFecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014 Dec 08; (94).J Vis Exp2014-12-08T00:00:002014Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection.25895005Allegretti JR, Barnes EL, Cameron AInflammatory bowel diseasesAre patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015 May; 21(5):1089-97.Inflamm Bowel Dis2015-05-01T00:00:002015Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis.Authorship 797103126535480Barnes EL, Allegretti JRJournal of clinical gastroenterologyAre Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016 10; 50(9):733-41.J Clin Gastroenterol2016-10-01T00:00:002016Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis.Authorship 846150126244647Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JRInflammatory bowel diseasesRisk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Nov; 21(11):2583-9.Inflamm Bowel Dis2015-11-01T00:00:002015Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease.Authorship 849159226288002Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik VInflammatory bowel diseasesEfficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015 Dec; 21(12):2879-85.Inflamm Bowel Dis2015-12-01T00:00:002015Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.Authorship 880245127086647Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JRAlimentary pharmacology & therapeuticsRecurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016 06; 43(11):1142-53.Aliment Pharmacol Ther2016-04-18T00:00:002016Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.2Assistant Professor1Associate Professor0Full Professor4Instructor3LecturerAuthorship 908691327542133Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss ACInflammatory bowel diseasesIncreased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 2016 09; 22(9):2182-90.Inflamm Bowel Dis2016-09-01T00:00:002016Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease.Authorship 91503816Authorship 914644227580384Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JRInflammatory bowel diseasesFecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 10; 22(10):2402-9.Inflamm Bowel Dis2016-10-01T00:00:002016Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.Authorship 953250528125559Goettel J, Kotlarz D, Illig D, Canavan J, Allegretti J, Hamilton M, Kelly R, Griffith A, Carellas M, Nelina A, Bousvaros A, Korzenik J, Snapper SInflammatory bowel diseasesO-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis. Inflamm Bowel Dis. 2017 Feb; 23 Suppl 1:S4.Inflamm Bowel Dis2017-02-01T00:00:002017O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis.Authorship 974349128357697Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik JDigestive diseases and sciencesPredictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017 06; 62(6):1590-1596.Dig Dis Sci2017-03-29T00:00:002017Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.SK683StacyKahnStacy Kahn, M.D.157833Kahn, StacyAssistant Professor of Pediatrics15680573Badia A, Riano F, Ravikoff J, Khouri R, Gonzalez-Hernandez E, Orbay JLThe Journal of hand surgeryDynamic intradigital external fixation for proximal interphalangeal joint fracture dislocations. J Hand Surg Am. 2005 Jan; 30(1):154-60.J Hand Surg Am2005-01-01T00:00:002005Dynamic intradigital external fixation for proximal interphalangeal joint fracture dislocations.75 Francis StBrigham and Womens HospitalGastroenterology - Thorn 1475 Francis StBoston02115MAAuthorship 986916128583769Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CRGastrointestinal endoscopyThe 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018 01; 87(1):18-29.Gastrointest Endosc2017-06-03T00:00:002017The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection.Authorship 10014524Authorship 10079862Authorship 1005815128814217Razik R, Osman M, Lieberman A, Allegretti JR, Kassam ZThe Medical journal of AustraliaFaecal microbiota transplantation for <em>Clostridium difficile</em> infection: a multicentre study of non-responders. Med J Aust. 2017 08 21; 207(4):159-160.Med J Aust2017-08-21T00:00:002017Faecal microbiota transplantation for <em>Clostridium difficile</em> infection: a multicentre study of non-responders.28840580Kelly CR, Allegretti JRDigestive diseases and sciencesFMT in IBD: What Have We Learned? Dig Dis Sci. 2017 10; 62(10):2618-2620.Dig Dis Sci2017-10-01T00:00:002017FMT in IBD: What Have We Learned?28858073Allegretti J, Eysenbach LM, El-Nachef N, Fischer M, Kelly C, Kassam ZInflammatory bowel diseasesThe Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future. Inflamm Bowel Dis. 2017 10; 23(10):1710-1717.Inflamm Bowel Dis2017-10-01T00:00:002017The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future.Authorship 1010370628723262Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JRGut microbesThe risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017 11 02; 8(6):574-588.Gut Microbes2017-09-12T00:00:002017The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.Authorship 1019404129020157Allegretti JR, Kao D, Sitko J, Fischer M, Kassam ZClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaEarly Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure. Clin Infect Dis. 2018 01 06; 66(1):134-135.Clin Infect Dis2018-01-06T00:00:002018Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure.Authorship 10257511Authorship 1025297129104129Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam ZClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationClassifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clin Gastroenterol Hepatol. 2018 11; 16(11):1832-1833.Clin Gastroenterol Hepatol2017-11-16T00:00:002017Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures.29104169Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer MClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesAsymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. 2018 Jul; 24(7):780.e1-780.e3.Clin Microbiol Infect2017-11-11T00:00:002017Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment.29188472Allegretti JR, Kassam Z, Chan WWDigestive diseases and sciencesSmall Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? Dig Dis Sci. 2018 01; 63(1):193-197.Dig Dis Sci2017-11-29T00:00:002017Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation?Authorship 10298111Authorship 10314201129246701Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, Torbeck M, Xu H, Ouyang F, Mozaffarian D, Allegretti JRClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationStool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2018 08; 16(8):1351-1353.Clin Gastroenterol Hepatol2017-12-12T00:00:002017Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection.